 |
Европейская академия
|
| В начало | Энциклопедия ЕАЕН | |
Энциклопедия Европейской академии естественных наук |
||
Liang
Chun
Liang Chun, male, born in 1962, Doctor of Philosophy (Biology) of Hong Kong University of Science and Technology, Deputy Director and Director of Cancer Research Center of Hong Kong University of Science and Technology; He is an internationally renowned scientist in molecular biology, cell biology, genetics, and cancer research; Chairman and Chief Scientific Officer of Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd.
Engaged in DNA replication, cell cycle and cancer mechanism research for more than 30 years; Collaborate with medical and pharmaceutical experts to study the molecular mechanisms of diseases, develop molecular detection methods and drugs. The research results have been published in the top international journal "Cell" (with over 30 influencing factors), and more than 60 papers have been published in other international journals, including 11 papers in the first region, with a total of over 300 influencing factors in the papers. The research results have a direct role in promoting DNA replication, cell cycle regulation, cell proliferation, cancer and other research fields. More than 40 invention patents have been applied for, of which 13 have been authorized; It is the first time to find DNA replication starting protein as a new anti-cancer target in the world, establish an international leading screening platform for original and highly selective targeted anti-cancer drugs, and develop new target inhibitor First in class tumor drugs. One of the FIC class of new anti-cancer drugs under development has a tumor inhibition rate of 100% in vivo, which shows the characteristics of high efficiency, low toxicity, and broad spectrum tumor suppression, and has entered China's clinical research.
梁纯，男，1962年出生，香港科技大学哲学（生物学）博士、香港科技大学癌症研究中心副主任、主任；为国际知名分子生物学、细胞生物学、遗传学及癌症研究科学家；恩康药业科技(广州)有限公司董事长、首席科学官。
从事DNA复制、细胞周期和癌症机制研究30余年；同时与医学和药学专家合作，研究疾病的分子机制，研发分子检测方法和药物。研究成果在国际顶级的《细胞》杂志（影响因子30多点），在其他国际杂志上发表论文60余篇，其中一区论文11篇，论文影响因子合计300余点。研究成果对DNA复制、细胞周期调控、细胞增殖以及癌症等研究领域具有直接推动作用。已申请40余项发明专利，其中13项已获授权；在国际上首次发现DNA复制起始蛋白为抗癌新靶点，建立国际领先的原创高选择性靶向抗癌药筛选平台，研发新靶点抑制剂First-in-class肿瘤新药，其中一个FIC一类在研抗癌新药的体内抑瘤率高达100%，显示了高效、低毒、广谱抑瘤的特点，并已进入中国临床研究。
| Энциклопедия ЕАЕН |